{"id":77030,"date":"2026-08-28T20:25:13","date_gmt":"2026-08-28T12:25:13","guid":{"rendered":"https:\/\/flcube.com\/?p=77030"},"modified":"2026-08-28T20:25:14","modified_gmt":"2026-08-28T12:25:14","slug":"gileads-bixlenvo-wins-fda-approval-as-smallest-once-daily-single-tablet-hiv-regimen","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77030","title":{"rendered":"Gilead&#8217;s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Gilead Sciences, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/GILD:NASDAQ\">NASDAQ: GILD<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved <strong>Bixlenvo (bictegravir 75 mg\/lenacapavir 50 mg)<\/strong>, the smallest once-daily single tablet regimen (STR) for the treatment of <strong>HIV<\/strong> in adults who are virologically suppressed. The approval reinforces <strong>Gilead&#8217;s<\/strong> leadership in antiretroviral therapy and expands its dominant HIV portfolio with a simplified, two-drug oral option.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>U.S. Food and Drug Administration (FDA)<\/strong><\/td><\/tr><tr><td>Approval Type<\/td><td>New product approval \u2013 single tablet regimen<\/td><\/tr><tr><td>Product<\/td><td><strong>Bixlenvo (bictegravir 75 mg\/lenacapavir 50 mg)<\/strong>, once-daily oral STR<\/td><\/tr><tr><td>Indication<\/td><td>Treatment of <strong>HIV<\/strong> in adults who are virologically suppressed<\/td><\/tr><tr><td>Date<\/td><td>27 Aug 2026<\/td><\/tr><tr><td>Next Steps<\/td><td>U.S. commercial launch of <strong>Bixlenvo<\/strong>; potential switching market from <strong>Biktarvy<\/strong> and multi-tablet regimens<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Bictegravir 75 mg + lenacapavir 50 mg fixed-dose combination<\/li>\n\n\n\n<li><strong>Component 1 \u2013 Bictegravir:<\/strong> Global guideline-recommended <strong>integrase strand transfer inhibitor (INSTI)<\/strong> with a high barrier to resistance<\/li>\n\n\n\n<li><strong>Component 2 \u2013 Lenacapavir:<\/strong> First-in-class <strong>capsid inhibitor<\/strong> with a novel mechanism of action and no cross-resistance to other antiretrovirals<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Smallest once-daily single tablet regimen for HIV, pairing two well-validated agents into a minimal pill-burden option<\/li>\n\n\n\n<li><strong>Administration:<\/strong> One pill, once daily \u2014 designed for patients seeking simplification from more complex regimens<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-artistry-1-amp-artistry-2\" class=\"wp-block-heading\">Clinical Evidence \u2013 ARTISTRY-1 &amp; ARTISTRY-2<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial<\/th><th>Design<\/th><th>Key Population<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td>ARTISTRY-1 (NCT05502341)<\/td><td>Phase 3 switch study<\/td><td>Virologically suppressed adults with HIV<\/td><td>Comparable efficacy in maintaining virologic suppression at Week 48<\/td><\/tr><tr><td>ARTISTRY-2 (NCT06333808)<\/td><td>Phase 3 switch study<\/td><td>Virologically suppressed adults, incl. those switching from <strong>Biktarvy<\/strong> or multi-tablet regimens<\/td><td>Comparable efficacy in maintaining virologic suppression at Week 48<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Across both Phase 3 trials, <strong>Bixlenvo<\/strong> demonstrated comparable efficacy to existing regimens in maintaining virologic suppression through Week 48 and was generally well tolerated, with no significant or new safety concerns identified. The data support switching virologically suppressed patients \u2014 including those on complex multi-tablet regimens or on <strong>Gilead&#8217;s<\/strong> flagship <strong>Biktarvy<\/strong> (bictegravir 50 mg\/emtricitabine 200 mg\/tenofovir alafenamide 25 mg) \u2014 to the streamlined two-drug STR.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Strategy:<\/strong> <strong>Bixlenvo<\/strong> extends <strong>Gilead&#8217;s<\/strong> HIV franchise, offering an internal switch path from <strong>Biktarvy<\/strong> that defends share against regimen simplification by competitors<\/li>\n\n\n\n<li><strong>Simplification Trend:<\/strong> The smallest once-daily STR addresses a persistent patient preference for lower pill burden in chronic HIV care<\/li>\n\n\n\n<li><strong>Differentiated Backbone:<\/strong> Lenacapavir&#8217;s first-in-class capsid mechanism \u2014 with no cross-resistance to other antiretrovirals \u2014 underpins <strong>Gilead&#8217;s<\/strong> long-acting and simplified regimen roadmap<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> The approval strengthens <strong>Gilead&#8217;s<\/strong> position against rival two-drug regimens in the switch market, where maintaining suppressed patients on simpler therapy is the key commercial battleground<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief contains forward-looking statements regarding commercial strategy, market adoption, and portfolio outlook. Actual results may differ materially due to regulatory, competitive, and other risks. Not investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":77032,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11,4908],"tags":[226,1025,15],"class_list":["post-77030","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","category-pic","tag-gilead-sciences","tag-nasdaq-gild","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead&#039;s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has approved Bixlenvo (bictegravir 75 mg\/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. The approval reinforces Gilead&#039;s leadership in antiretroviral therapy and expands its dominant HIV portfolio with a simplified, two-drug oral option.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77030\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead&#039;s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has approved Bixlenvo (bictegravir 75 mg\/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. The approval reinforces Gilead&#039;s leadership in antiretroviral therapy and expands its dominant HIV portfolio with a simplified, two-drug oral option.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77030\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T12:25:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T12:25:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2802.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77030#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77030\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead&#8217;s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen\",\"datePublished\":\"2026-08-28T12:25:13+00:00\",\"dateModified\":\"2026-08-28T12:25:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77030\"},\"wordCount\":450,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77030#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2802.webp\",\"keywords\":[\"Gilead Sciences\",\"NASDAQ: GILD\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77030#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77030\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77030\",\"name\":\"Gilead's Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77030#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77030#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2802.webp\",\"datePublished\":\"2026-08-28T12:25:13+00:00\",\"dateModified\":\"2026-08-28T12:25:14+00:00\",\"description\":\"Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has approved Bixlenvo (bictegravir 75 mg\\\/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. The approval reinforces Gilead's leadership in antiretroviral therapy and expands its dominant HIV portfolio with a simplified, two-drug oral option.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77030#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77030\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77030#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2802.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2802.webp\",\"width\":1080,\"height\":608,\"caption\":\"Gilead's Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77030#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead&#8217;s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead's Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen - Insight, China&#039;s Pharmaceutical Industry","description":"Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has approved Bixlenvo (bictegravir 75 mg\/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. The approval reinforces Gilead's leadership in antiretroviral therapy and expands its dominant HIV portfolio with a simplified, two-drug oral option.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77030","og_locale":"en_US","og_type":"article","og_title":"Gilead's Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen","og_description":"Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has approved Bixlenvo (bictegravir 75 mg\/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. The approval reinforces Gilead's leadership in antiretroviral therapy and expands its dominant HIV portfolio with a simplified, two-drug oral option.","og_url":"https:\/\/flcube.com\/?p=77030","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-28T12:25:13+00:00","article_modified_time":"2026-08-28T12:25:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2802.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77030#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77030"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead&#8217;s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen","datePublished":"2026-08-28T12:25:13+00:00","dateModified":"2026-08-28T12:25:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77030"},"wordCount":450,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=77030#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2802.webp","keywords":["Gilead Sciences","NASDAQ: GILD","Product approvals"],"articleSection":["Company","Drug","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77030#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77030","url":"https:\/\/flcube.com\/?p=77030","name":"Gilead's Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=77030#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=77030#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2802.webp","datePublished":"2026-08-28T12:25:13+00:00","dateModified":"2026-08-28T12:25:14+00:00","description":"Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has approved Bixlenvo (bictegravir 75 mg\/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. The approval reinforces Gilead's leadership in antiretroviral therapy and expands its dominant HIV portfolio with a simplified, two-drug oral option.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77030#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77030"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=77030#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2802.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2802.webp","width":1080,"height":608,"caption":"Gilead's Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77030#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead&#8217;s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2802.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77030"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77030\/revisions"}],"predecessor-version":[{"id":77033,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77030\/revisions\/77033"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/77032"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}